Precautions for Ixazomib

Ixazomib is available in capsule dosage form and is a prescription-only medicine, which must be purchased with a doctor’s prescription.

Precautions for Ixazomib

During treatment with this medicine, regular medical follow-ups are of great importance to ensure its efficacy. Blood tests may be required to monitor for adverse reactions.

The use of this medicine during pregnancy may cause fetal harm. For women of childbearing potential, the doctor may arrange tests to confirm non-pregnancy before the initiation of treatment. Effective contraceptive measures should be taken during the treatment period and within 90 days after the last dose. Male patients whose female partners are of childbearing potential must also take effective contraceptive measures during the treatment period and for at least 90 days after the last dose. If pregnancy is suspected during the medication period, the doctor should be informed immediately.

This medicine may reduce platelet count and affect normal blood coagulation function. If abnormal bleeding or bruising, black tarry stools, or pinpoint red spots on the skin occur during the medication period, medical attention should be sought immediately.

Anti-cancer drugs often cause diarrhea, constipation, nausea, or vomiting, which may occur even if preventive medications have been administered. Consult your doctor or nurse for other methods to control these side effects.

Pharmacological Information of Ixazomib

Mechanism of Action

A reversible proteasome inhibitor; it preferentially binds to and inhibits the chymotrypsin-like activity of the β5 subunit of the 20S proteasome.

Absorption

Absolute bioavailability: 58%.

Time to reach peak plasma concentration (Tmax): 1 hour.

Studies in patients who received a single 4 mg dose showed that a high-fat meal decreased the area under the plasma concentration-time curve (AUC) by 28% and the peak plasma concentration (Cmax) by 69%.

Distribution

Plasma protein binding rate: 99% bound to plasma proteins; it can distribute into red blood cells, with a whole blood to plasma concentration ratio of 10.

Volume of distribution: 543 liters.

Metabolism

It is mainly metabolized by various CYP enzymes and non-CYP proteins, which serves as the primary elimination pathway.

Elimination

Half-life (t½): 9.5 days.

Systemic clearance: 1.9 liters per hour.

Excretion: 62% via urine (< 3.5% as unchanged drug); 22% via feces.

Administration Method of Ixazomib

Oral Administration

The treatment cycle is 4 weeks, with one dose taken on a fixed day each week during the first 3 weeks, approximately at the same time each time.

The capsules should be taken at least 1 hour before a meal or 2 hours after a meal.

The capsule must be swallowed whole with water and must not be crushed, chewed, or opened.

Precautions to Be Informed to Patients

Emphasize the importance of strictly following all medication instructions.

Advise patients to take the recommended dose; overdose may lead to death.

Missed Dose or Dose Adjustment After Vomiting

Delayed or missed dose: A missed dose can be supplemented only if the interval from the next scheduled dose is ≥ 72 hours; a double dose must not be taken to make up for the missed one.

Vomiting after medication: No supplementary dose is needed; the next dose should be taken at the originally scheduled time.